Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SHR3680 in Liver Impairment
NCT04631549Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rezvilutamide in prostate cancer (PCa) (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Status: unknown.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04631549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631549.